The Tisch Cancer Institute

  1. About
researchers in a lab

Scholars Program

Scholars Program

Advances in genetics, immunology, and cell biology are enabling a deeper understanding of cancer prevention and treatment—offering the potential to better address and even cure cancer. The Tisch Cancer Institute Scholars Program builds on this potential by supporting fresh approaches from up-and-coming scientists.

Our Scholars Program provides promising early to mid-career investigators at the Icahn School of Medicine at Mount Sinai with annual awards to support their innovative cancer research. The Scholars Program is made possible through donor support.

By supporting The Tisch Cancer Institute Scholars, you can: 

  • Fund a critical need. Young investigators face limited options for funding from traditional sources, such as the National Institutes of Health. The Tisch Cancer Institute Scholars Program enables these promising scientists to put their research plan into action quickly.
  • Ensure Mount Sinai retains the brightest minds in cancer research. Donors to The Tisch Cancer Institute Scholars Program provide the kind of flexible, reliable funding that helps recruit the most brilliant investigators—and retain them here at Mount Sinai.
  • Fund groundbreaking research at the outset. Fueled by early support, our Scholars will be better positioned to receive larger grants, publish their findings in leading journals, and train the next generation of researchers. Your contribution helps our young investigators accumulate the preliminary data needed to take their translational research from concept to actualization. As a result, patients will have access to innovative treatments sooner.

Eligibility for the Scholars Program

The Tisch Cancer Institute Scholars Program is open to early- to mid-career cancer faculty throughout the Mount Sinai Health System who are engaged in cancer-related research. We are particularly interested in projects designed to generate the preliminary data needed to secure external funding from the National Institutes of Health or other sources. We select recipients on a competitive basis through an expert review committee. The committee ensures that the process is objective and thorough, and balances support for basic, clinical, and translational research. 

Find A Clinical Trial Make a Gift Discover Careers

Meet Our Recent Scholars

Joshua Brody headshot

Joshua Brody, MD

 Cancer immunotherapy has revolutionized patient care by allowing the patient’s immune system to target specific antigens present on cancerous cells, but not healthy cells. One major limitation of T-cell-based immunotherapies is a phenomenon known as “antigen escape,” which occurs when a subset of cancer cells loses the targeted antigen. This project tested several therapies that can prevent antigen escape by boosting a process called bystander killing, where targeted tumor cells are destroyed along with bystander tumor cells, regardless of antigen expression, and thereby increase T-cell efficacy.

View Profile
Carousel Background Image 2

Joshua Brody, MD

 Cancer immunotherapy has revolutionized patient care by allowing the patient’s immune system to target specific antigens present on cancerous cells, but not healthy cells. One major limitation of T-cell-based immunotherapies is a phenomenon known as “antigen escape,” which occurs when a subset of cancer cells loses the targeted antigen. This project tested several therapies that can prevent antigen escape by boosting a process called bystander killing, where targeted tumor cells are destroyed along with bystander tumor cells, regardless of antigen expression, and thereby increase T-cell efficacy.

View Profile
Carousel Background Image 2

David Dominguez-Sola, MD, PhD

Dr. Dominguez-Sola’s research aims to understand how oncogenes contribute to uncontrolled tumor growth and resistance to cancer treatment. The findings of this study may provide new insights into cancer biology and could lead to innovative treatment strategies for a wide range of cancer patients.

View Profile
Joshua Brody headshot

Joshua Brody, MD

 Cancer immunotherapy has revolutionized patient care by allowing the patient’s immune system to target specific antigens present on cancerous cells, but not healthy cells. One major limitation of T-cell-based immunotherapies is a phenomenon known as “antigen escape,” which occurs when a subset of cancer cells loses the targeted antigen. This project tested several therapies that can prevent antigen escape by boosting a process called bystander killing, where targeted tumor cells are destroyed along with bystander tumor cells, regardless of antigen expression, and thereby increase T-cell efficacy.

View Profile
David Dominguez-Sola headshot

David Dominguez-Sola, MD, PhD

Dr. Dominguez-Sola’s research aims to understand how oncogenes contribute to uncontrolled tumor growth and resistance to cancer treatment. The findings of this study may provide new insights into cancer biology and could lead to innovative treatment strategies for a wide range of cancer patients.

View Profile
Emily Gallagher headshot

Emily Gallagher, MD, PhD

Dr. Gallagher’s research focuses on investigating the correlation between diabetes and cancer development, particularly aggressive forms like triple negative breast cancer (TNBC) and how high insulin levels contribute to tumor growth. This research has the potential to significantly reduce the risk of TNBC in individuals with high insulin levels.

View Profile

Resources For You

Cancer Centers of Excellence
Patient Care
Oncological Sciences
Division of Hematology and Medical Oncology
Residencies and Fellowships
Shared Resources

Contact Us

Ashley Seymour
Associate Director of Development

718-306-8974
Email